Parker Waichman LLP Headlines by Topic
Tysabri
Widower Sues Over Wife's Death During Trial for Biogen Drug
Jun 21, 2005
| AP
A Colorado widower whose wife died after participating in a clinical trial for one of Biogen Idec's multiple sclerosis drugs has sued the company,...
WITH THE POSSIBILITY OF YET A FIFTH CASE OF BRAIN INFECTION BEING LINKED TO THE MULTIPLE SCLEROSIS DRUG (TYSABRI), IS THE HOPE OF SAVING THE DRUG A REALISTIC ONE?
Jun 14, 2005
| www.Newsinferno.com
The FDA has been informed by Biogen Idec Inc. that a fifth person has developed a rare brain disease known as progressive multifocal...
CORRECTION: MULTIPLE SCLEROSIS DRUG (TYSABRI) MAY HAVE BEEN RESPONSIBLE FOR FOURTH CASE OF RARE BRAIN DISEASE
Jun 4, 2005
| www.Newsinferno.com
Yesterday, we reported that the FDA had been informed by Biogen Idec Inc. that a fourth person may have died from a rare and often fatal brain...
MULTIPLE SCLEROSIS DRUG (TYSABRI) MAY HAVE BEEN RESPONSIBLE FOR FOURTH DEATH FROM RARE BRAIN DISEASE
Jun 3, 2005
| www.Newsinferno.com
The FDA has been informed by Biogen Idec Inc. that a fourth person may now have died from a rare brain disease known as progressive multifocal...
Warning Didn't Slow Approval of MS Drug
Mar 2, 2005
| Los Angeles Times
A multiple sclerosis drug pulled off the market after a patient died was approved by the Food and Drug Administration even though a prominent...
Makers Take MS Drug Tysabri Off Market After Death
Mar 1, 2005
| AP
The makers of Tysabri, a new drug used to treat multiple sclerosis, said yesterday that they are voluntarily suspending sales of the drug because one...
Biogen, Elan Voluntarily Withdraw Tysabri
Feb 28, 2005
| AP
Biogen Idec Inc. and Elan Corp. announced Monday they have voluntarily withdrawn a recently approved drug used to treat multiple sclerosis after one...
Biogen, Elan Halt MS Drug After Patient Death
Feb 28, 2005
| AP
Biogen Idec (BIIB) and Elan Corp. Plc (ELN) on Monday suspended sales of their much-heralded new multiple sclerosis drug after a patient died from a...
BIOGEN IDEC AND ELAN ANNOUNCE VOLUNTARY SUSPENSION OF TYSABRI
Feb 28, 2005
| www.biogen.com
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today a voluntary suspension in the marketing of TYSABRI® (natalizumab),...
Suspended Marketing of Tysabri (natalizumab)
Feb 28, 2005
| www.fda.gov
FDA is issuing this public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (natalizumab) due to...
ParkerWaichmanLLP
@ParkerWaichman
parkerwaichman
parkerwaichmanllp